| Irreversible inhibition of cytosolic thioredoxin reductase 1 as a mechanistic basis for anticancer therapy WC Stafford, X Peng, MH Olofsson, X Zhang, DK Luci, L Lu, Q Cheng, ... Science translational medicine 10 (428), eaaf7444, 2018 | 195 | 2018 |
| The 19S Deubiquitinase inhibitor b-AP15 is enriched in cells and elicits rapid commitment to cell death X Wang, W Stafford, M Mazurkiewicz, M Fryknäs, S Brjnic, X Zhang, ... Molecular pharmacology 85 (6), 932-945, 2014 | 79 | 2014 |
| Inhibition of thioredoxin reductase 1 by porphyrins and other small molecules identified by a high-throughput screening assay S Prast-Nielsen, TS Dexheimer, L Schultz, WC Stafford, Q Cheng, J Xu, ... Free Radical Biology and Medicine 50 (9), 1114-1123, 2011 | 44 | 2011 |
| Redox effects and cytotoxic profiles of MJ25 and auranofin towards malignant melanoma cells MCC Sachweh, WC Stafford, CJ Drummond, AR McCarthy, M Higgins, ... Oncotarget 6 (18), 16488, 2015 | 39 | 2015 |
| Indolin-2-one compounds targeting thioredoxin reductase as potential anticancer drug leads KK Kaminska, HC Bertrand, H Tajima, WC Stafford, Q Cheng, W Chen, ... Oncotarget 7 (26), 40233, 2016 | 24 | 2016 |
| Sulfinylpyridines and their use in the treatment of cancer B Pelcman, O Orwar, W Stafford, K Andersson US Patent 11,208,384, 2021 | 7 | 2021 |
| Heterocyclylsulfonyl-substituted pyridines and their use in the treatment of cancer B Pelcman, W Stafford US Patent 11,168,069, 2021 | 6 | 2021 |
| Hydrocarbylsulfonyl-substituted pyridines and their use in the treatment of cancer B Pelcman, E Suna, W Stafford, M Priede US Patent 11,161,815, 2021 | 6 | 2021 |
| Heteroarylsulfonyl-substituted pyridines and their use in the treatment of cancer B Pelcman, E Suna, W Stafford, M Priede US Patent 11,028,067, 2021 | 5 | 2021 |
| Irreversible inhibition of cytosolic thioredoxin reductase 1 as a mechanistic basis for anticancer therapy, Sci. Transl. Med. 10 (2018) WC Stafford, X Peng, MH Olofsson, X Zhang, DK Luci, L Lu, Q Cheng, ... | 5 | |
| Pyridines and their use in the treatment of cancer ESJ Arnér, WC Stafford, NP Coussens, DK Luci, DJ Maloney, A Simeonov, ... US Patent 10,899,710, 2021 | 4 | 2021 |
| Irreversible inhibition of cytosolic thioredoxin reductase 1 as a mechanistic basis for anticancer therapy. Sci Transl Med. 2018; 10 WC Stafford, X Peng, MH Olofsson, X Zhang, DK Luci, L Lu | 3 | |
| Tricyclic compounds and their use in the treatment of cancer ESJ Arnér, WC Stafford, NP Coussens, DK Luci, DJ Maloney, A Simeonov, ... US Patent 10,881,653, 2021 | 2 | 2021 |
| Sulfinylpyridines and their use in the treatment of cancer B Pelcman, O Orwar, W Stafford, K Andersson US Patent App. 17/551,925, 2022 | | 2022 |
| Hydrocarbylsulfonyl-substituted pyridines and their use in the treatment of cancer B Pelcman, E Suna, W Stafford, M Priede US Patent App. 17/514,288, 2022 | | 2022 |
| Pyridazinones and their use in the treatment of cancer ESJ Arnér, WC Stafford, NP Coussens, DK Luci, DJ Maloney, A Simeonov, ... US Patent 11,110,089, 2021 | | 2021 |
| Pyridines à substitution hétéroarylsulfonyle et leur utilisation dans le traitement du cancer B Pelcman, M Priede, W Stafford, E Suna | | 2019 |
| Pyridines à substitution hétérocyclylsulfonyle et leur utilisation dans le traitement du cancer B Pelcman, W Stafford | | 2019 |
| Sulfinylpyridines et leur utilisation dans le traitement du cancer K Andersson, O Orwar, B Pelcman, W Stafford | | 2019 |
| Pyridines à substitution hydrocarbylsulfonyle et leur utilisation dans le traitement du cancer B Pelcman, M Priede, W Stafford, E Suna | | 2019 |
